This Article Full Text Full Text (PDF) Supplemental Data and Journal Club All Versions of this Article: clinchem.2009.137323v1 56/2/281    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Google Scholar Articles by Lopez, M. F. Articles by Nelson, R. W. PubMed PubMed Citation Articles by Lopez, M. F. Articles by Nelson, R. W. Related Collections Proteomics and Protein Markers

Selected Reaction Monitoring–Mass Spectrometric Immunoassay Responsive to Parathyroid Hormone and Related Variants

¹ ThermoFisher Scientific BRIMS, Cambridge, MA; ² VAST Scientific, Cambridge, MA; ³ Mayo Clinic College of Medicine, Rochester, MN; ⁴ Biodesign Institute, Arizona State University, Tempe, AZ; ⁵ Intrinsic Bioprobes, Tempe, AZ.

^aAddress correspondence to this author at: The Biodesign Institute, Arizona State University, P.O. Box 876601, Tempe, AZ 85287. Fax 480-727-9464; e-mail randal.nelson{at}asu.edu

Background: Parathyroid hormone (PTH) assays able to distinguish between full-length PTH (PTH1–84) and N-terminally truncated PTH (PTH7–84) are of increasing significance in the accurate diagnosis of endocrine and osteological diseases. We describe the discovery of new N-terminal and C-terminal PTH variants and the development of selected reaction monitoring (SRM)-based immunoassays specifically designed for the detection of full-length PTH [amino acid (aa)1–84] and 2 N-terminal variants, aa7–84 and aa34–84.

Methods: Preparation of mass spectrometric immunoassay pipettor tips and MALDI-TOF mass spectrometric analysis were carried out as previously described. We used novel software to develop SRM assays on a triple-quadrupole mass spectrometer. Heavy isotope-labeled versions of target peptides were used as internal standards.

Results: Top-down analysis of samples from healthy individuals and renal failure patients revealed numerous PTH variants, including previously unidentified aa28–84, aa48–84, aa34–77, aa37–77, and aa38–77. Quantitative SRM assays were developed for PTH1–84, PTH7–84, and variant aa34–84. Peptides exhibited linear responses (R² = 0.90–0.99) relative to recombinant human PTH concentration limits of detection for intact PTH of 8 ng/L and limits of quantification of 16–31 ng/L depending on the peptide. Standard error of analysis for all triplicate measurements was 3%–12% for all peptides, with <5% chromatographic drift between replicates. The CVs of integrated areas under the curve for 54 separate measurements of heavy peptides were 5%–9%.

Conclusions: Mass spectrometric immunoassays identified new clinical variants of PTH and provided a quantitative assay for these and previously identified forms of PTH.

The following articles in journals at HighWire Press have cited this article:

				G. G. Klee Harmonization and Standardization of Thyroid Function Tests Clin. Chem., June 1, 2010; 56(6): 879 - 880. [Full Text] [PDF]

				C. R. Borges, D. S. Rehder, J. W. Jarvis, M. R. Schaab, P. E. Oran, and R. W. Nelson Full-Length Characterization of Proteins in Human Populations Clin. Chem., February 1, 2010; 56(2): 202 - 211. [Abstract] [Full Text] [PDF]